Camilleri M, Carlson P, Acosta A, Busciglio I, Nair AA, Gibbons SJ, Farrugia G, Klee EW. RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study. Am J Physiol Gastrointest Liver Physiol 306: G1089 -G1098, 2014. First published April 24, 2014; doi:10.1152/ajpgi.00068.2014.-Our aim was to conduct a pilot case-control study of RNA expression profile using RNA sequencing of rectosigmoid mucosa of nine females with -diarrheapredominant irritable bowel syndrome (IBS-D) with accelerated colonic transit and nine female healthy controls. Mucosal total RNA was isolated and purified, and next-generation pair-end sequencing was performed using Illumina TruSeq. Analysis was carried out using a targeted approach toward 12 genes previously associated with IBS and a hypothesis-generating approach. Of the 12 targeted genes tested, patients with IBS-D had decreased mRNA expression of TNFSF15 (fold change controls to IBS-D: 1.53, P ϭ 0.01). Overall, up-and downregulated mRNA expressions of 21 genes (P ϭ 10 Ϫ5 to 10 Ϫ8 ; P values with false detection rates are shown) were potentially relevant to IBS-D including the following: neurotransmitters [P2RY4 (P ϭ 0.001), vasoactive intestinal peptide (VIP, P ϭ 0.02)]; cytokines [CCL20 (P ϭ 0.019)]; immune function [C4BPA complement cascade (P ϭ 0.0187)]; interferon-related [IFIT3 (P ϭ 0.016)]; mucosal repair and cell adhesion [trefoil protein (TFF1, P ϭ 0.012)], retinol binding protein [RBP2 (P ϭ 0.017)]; fibronectin (FN1, P ϭ 0.009); and ion channel functions [guanylate cyclase (GUCA2B, P ϭ 0.017), PDZ domain-containing protein 3 (PDZD3, P ϭ 0.029)]. Ten genes associated with functions related to pathobiology of IBS-D were validated by RT-PCR. There was significant correlation in fold changes of the selected genes (Rs ϭ 0.73, P ϭ 0.013). Up-or downregulation of P2RY4, GUC2AB, RBP2, FNI, and C4BPA genes were confirmed on RT-PCR, which also revealed upregulation of farnesoid X receptor (FXR) and apical sodium-coupled bile acid transporter (IBAT/ASBT). RNA-Seq and RT-PCR analysis of rectosigmoid mucosa in IBS-D show transcriptome changes that provide the rationale for validation studies to explore the role of mucosal factors in the pathobiology of IBS-D.
THE CAUSE OF LOOSE CONSISTENCY of bowel movements in patients with irritable bowel syndrome with diarrhea (IBS-D) is attributed in part to acceleration of colonic transit, which is documented in ϳ45% of patients with IBS-D (11), providing less time for reabsorption of water in the colon (16) . Circulating postprandial levels of serotonin are increased in patients with IBS-D (17; 21) . Increased duodenal and rectosigmoid expression of secretory transmitters and fecal excretion of granins are also documented (18; 19; 29) although it is unclear whether these result in intestinal fluid and electrolyte secretion or accelerated transit with reduced colonic fluid absorption. There is one study that suggested that the ileal mucosa of patients with IBS, compared with that of healthy controls, responds to infusion of bile acids with greater fluid and electrolyte secretion (18) . Mutations in the gene GUCY2C that controls the secretory guanylate cyclase C receptor have been reported in an extensive family who presented with chronic symptoms suggestive of IBS-D (20) .
The mucosal functions of patients with IBS-D and controls appear to differ (7) . IBS has been associated with changes in the rectosigmoid mucosal expression of immune and nonimmune protective factors, such as barrier function and mucus secretion (2) . The literature to date (2; 4; 5; 8; 12; 22; 36; 39 -41; 44; 45) is summarized in Table 1 . However, there are only a few examples, typically derived from assessments of single genes in relatively small numbers of patients and controls, where the inherited genotype has been associated with altered mucosal gene expression. For example, differential expression of the TNFSF15 gene, which is associated with IBS, has been linked with functional alterations of mucosal immune and protective functions (36; 45) . Although genotype can clearly influence the expression of related proteins in the colonic mucosa, function is more closely reflected in the expression of mRNA in the tissue. There is also evidence of alterations in jejunal mucosal abnormalities in the expression and distribution of apical junction complex proteins, specifically, increased protein expression of claudin-2, reduced occludin phosphorylation, enhanced redistribution from the membrane to the cytoplasm (24) , increased myosin kinase expression, reduced myosin phosphatase, and, consequently, enhanced phosphorylation of myosin (24) . In addition, the Barcelona group also reported that expression of zonula occludens 1 (ZO-1) was reduced in IBS-D at both gene and protein level, with protein redistribution from the tight junction to the cytoplasm (25) . In a prior study, we have demonstrated a borderline significant difference in the ZO-1 intensity score in the small bowel mucosa (P ϭ 0.06) of patients with IBS-D, compared with healthy controls with lower intensity in HLA-DQ2/8-positive relative to HLA-DQ2/8-negative patients with IBS-D (39) .
The development of next-generation RNA sequencing provides a novel opportunity to examine the entire transcriptome. Analysis of differential expression in well-matched patients and controls has the potential to assess differences in the transcriptome that may modify the function of the tissue (e.g., mucosa) in the disease of interest.
Our hypothesis was that RNA expression of mucosal biopsies from patients with IBS-D (with previously demonstrated accelerated colonic transit) differs from that of healthy controls. The aim of the study was to conduct RNA sequencing in stored mucosal samples obtained from the rectosigmoid region of nine female patients with IBS-D (with previously demonstrated accelerated colonic transit) and nine female healthy controls. We approached this aim using two strategies: first, we examined differential expression in the following 12 "targeted" genes associated with IBS in the literature : 5-HTTLPR,  TNFSF15, FAAH, CNR1, KLB, FGFR4, GPBAR1, TLR9,  C11orf30, ORMDL3, NPSR1 , and HLA2/8; second, we sought associations with differential expression of any other gene mRNA, independent of any a priori hypothesis, that is, an "unbiased analysis" intended for hypothesis generation. The results obtained for 10 of the genes of interest were validated by a quantitative RT-PCR. An ancillary study used pathway analyses to explore how any identified alterations in mRNA expression might mediate the pathobiology of IBS.
MATERIALS AND METHODS
Design. We conducted a case-control study of a convenient number of participants in this pilot study. We used stored samples from patients who had consented to the use of biospecimens (for future research) in prior studies (2; 38) conducted at Mayo Clinic in Rochester, MN. These samples were obtained in nine female patients with IBS-D and nine female healthy controls. RNA sequencing was conducted by the Mayo Medical Genomics Facility and bioinformatics by the Mayo Bioinformatics Core Facility to interpret differential expression in patients and controls. The study was approved by Mayo Clinic Institutional Review Board (IRB no. 13-001595, date of approval 3/13/2013).
Selection of participants. We examined, using RNA sequencing, the RNA expression of rectosigmoid mucosal biopsies from nine female patients with IBS-D (age range, 25- Sample storage. Participants' rectosigmoid biopsies were preserved in a solution of RNALater, stored at Ϫ80°C. Total RNA was isolated using the RNeasy Plus Mini (Qiagen, Valencia, CA). Quality of the extracted RNA was assessed by the Mayo Gene Expression Core using Agilent Bioanalyzers. All samples had RNA Integrity Numbers (RIN) greater than 7.0.
In-depth RNA sequencing of colonic mucosa. RNA sequencing was performed as paired-end 51 base reads on an Illumina HiSeq 2000 with three samples multiplexed per lane, using TruSeq SBS Sequencing Kit Version 3. Base calling was performed using Illumina's RTA version 1.12.4.2.
Bioinformatics analysis workflow. Analysis of each sample (alignment statistics, in-depth quality control metrics, gene and exon expression levels, fusion transcripts, and single nucleotide variants) was done using Mayo Clinic's MAPRSeq v1.0, a computational workflow for analysis of RNA-Seq. Differential expression between samples from patients with IBS-D and healthy controls was computed using edgeR algorithm (32) . EdgeR [or empirical analysis of digital gene expression in R (an open source programming environment)] is a bioconductor software package for examining differential expression of replicated count data; it involves determining whether counts for a transcript or exon are significantly different across experimental conditions. An important summary statistic is the number of reads in a class; for RNA-Seq, this read count has been found to be linearly related to the abundance of the target transcript (27) . Further details of the analysis, including bioinformatics, are included in Supplemental Materials.
Comparison of expressions in rectosigmoid mucosa from IBS-D and healthy participants. Gene expression variation was examined in the following genes, which have been associated with IBS in the literature based on genotype association studies (9; 39): 5-HTTLPR, TNFSF15, FAAH, CNR1, KLB, FGFR4, TGR5 (GPBAR1), PRDM1 (BLIMP1), TLR9, C11orf30, ORMDL3, NPSR1, and HLA2/8. The association of TNFSF15 with IBS symptom phenotype was significant with false detection rate (FDR) correction, and the strongest association was with constipation-predominant IBS (IBS-C) (45) . Of these 13 genes, the association with colonic transit has been reported in 10, and the association of KLB was significant with FDR correction (43) . In the published literature, no significant association with colonic transit was found with 5-HTTLPR, TNFSF15, or FGFR4 as individual genetic risk factors. However, FGFR4 significantly influenced the effect of KLB on colonic transit (43) , and HLADQ2/8 significantly altered the effect of gluten on gut permeability (38) and was associated with accelerated small bowel transit in patients with IBS-D (37), in addition to the association with colonic transit (39) . The second experimental approach assessed differential expression of any other gene mRNA, independent of any a priori hypothesis, that is an "unbiased" or hypothesis-generating analysis. An ancillary investigation used pathway analysis to assess the genes identified as differentially expressed by edgeR (adjusted P Ͻ 0.05).
mRNA expression using quantitative RT-PCR. To confirm the results of the RNA-Seq study, we submitted the mRNA from these biopsies to quantitative RT-PCR using the Qiagen RT 2 assays, which use a Sybr Green detection method. Thus we evaluated 20 genes of interest, including 10 (identified in Fig. 2 ) of those with significant P values on RNA-Seq that are associated with functions related to pathobiology of IBS-D, as well as other genes related to tight junction proteins (CLDN1, OCLN, ZO-1), bile acid homeostasis, receptor or absorption [FGFR4, GPBAR1, FXR, IBAT/ASBT (SLC10A2)], serotonin transporter protein (SLC6A4), and immune modulation (TNFSF15). The latter genes were selected based on recent data acquired in other studies of IBS-D in our laboratory or in the literature (1; 3; 37; 38; 45).
Briefly, total RNA was purified from human rectosigmoid tissue using the Qiagen RNAeasy Plus kit (Qiagen), including on-column DNAse treatment to remove genomic DNA. RNA quality was assessed by Agilent Bioanalyzer, and 0.5 g RNA (RINϾ7) was reverse transcribed using the RT 2 First Strand Kit (Qiagen). Resulting cDNA was amplified and gene expression quantified by Custom RT 2 PCR Array (Qiagen) using a 7300 Real-time PCR Machine (Applied Biosystems, Foster City, CA). In this custom profile, we included 20 candidate genes, two housekeeping genes for normalization, and three control genes to assure reaction quality (see Supplemental Materials, gene expression method by RT-PCR). Each assay utilizes a proprietary and experimentally verified algorithm for designing gene-specific qPCR primers with uniform PCR efficiency and amplification conditions. The assay was conducted as recommended by the supplier (Qiagen). For data analysis, the RT 2 Profiler PCR Array Data Analysis v3.5 software package was used. This package uses ⌬⌬ CT-based fold change calculations and Student's t-test (two-tail, equal variance: http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php?targetϭ upload) to assess the differences in mRNA fold changes between IBS-D and healthy control groups. In addition, we determined the Spearman correlation between by RNA-Seq and RT-PCR.
RESULTS
Sequence statistics based on sample analysis demonstrating quality control of the sequencing method. The sequence statistics showed an average of 118,760,446 (min/max 99,967,896/ 150,273,460) total reads per sample was obtained, which is above the minimum of 50 million reads necessary for RNA sequencing analysis: 84.5% mapped to the genome and 12.9% to the splice-site junction reference sequence set; 2.6% did not map for various technical reasons. Thus extensive expression data were available from all cases and controls.
mRNA expression of genes previously associated with IBS-D: hypothesis-based analysis. Gene expression variation was examined in the following genes, which have been associated with IBS in the literature:
5-HTTLPR, TNFSF15, FAAH, CNR1, KLB, FGFR4, TGR5 (GPBAR1), PRDM1(BLIMP1), TLR9, C11orf30, ORMDL3, NPSR1, and HLA2/8 (Table 2 shows gene expression variations in genes analyzed by DE Seq and edgeR).
There was decreased mRNA expression of TNFSF15 in rectosigmoid mucosa in nine patients with IBS-D compared with biopsies from nine healthy controls; the relative decrease in TNFSF15 expression was about 70% (Table 2) . No other changes in expression of genes previously associated with IBS were found. (Fig. 1) ] with an FDR-corrected P value of P Ͻ 0.05; the entire list of 21 genes with differentially expressed mRNA is shown in Table 3 . The functions of these 21 genes are further described in Table 4 . Many of the genes could be mapped to several biologically relevant pathways or mechanisms in IBS-D, as summarized here. Neurotransmitter functions were demonstrated when P2RY4 and VIP showed higher expression in IBS-D compared with healthy controls. Ion channel functions were upregulated in IBS-D relative to healthy controls; GUCA2B receptor associated with enterocyte chloride channel activation in response to uroguanylin and PDZD3 (also known as IKEPP, PDZK2, NHERF4); this PDZ protein associates with guanylate cyclase C and regulates cGMP production following receptor stimulation and mediates chloride secretion. Cytokines and complement were examined, and C4BPA complement cascade and CCL20 showed higher expression in IBS-D compared with healthy controls. Regarding immune function, TNFSF15 [P ϭ 0.01 (Table 2) Figure 2 demonstrates a comparison of fold changes between patients with IBS and healthy subjects in mRNA expression levels, as measured by RNA-Seq and RT Q-PCR. This includes 10 selected genes identified by RNA-Seq that are, at least theoretically, associated with functions related to pathobiology of IBS-D. In general, there was a significant Spearman correlation between fold change expression by the two techniques [Rs ϭ 0.73, P ϭ 0.013 (Fig. 2)] .
Comparison of RNA-Seq fold expression with results on RT-PCR.
The RT-PCR results mirror those of RNA-Seq in terms of the up-or downregulation of genes in IBS-D relative to healthy controls. In addition (Table 5) , the RT-PCR identified significant upregulation (P Ͻ 0.05) of P2RY4 (also significant on RNA-Seq) and of C4BPA, borderline significant upregulation of GUCA2B and RBP2, and significant downregulation of FN1. Thus results of 5 of the 10 genes selected from RNA-Seq analysis were confirmed on RT-PCR.
Moreover (Table 5) , the RT-PCR demonstrated borderline decreased expressions of the tight junction protein claudin 1 and an immune modulator (TNFSF15). Conversely, there was significantly increased expression of the nuclear receptor, FXR, and borderline increased expression of apical sodium-coupled bile acid transporter (IBAT/ASBT). Table 6 shows that the altered mRNA expression of these genes was not detected on RNA-Seq.
DISCUSSION
This is the first report of an RNA-Seq study of the expression of genes in patients with IBS-D compared with controls. This analysis builds on a prior analysis that we conducted several years ago, in which we examined the rectosigmoid mucosal expression of RNA from 30 patients with IBS conducted using Affimetrix Gene chips. The former study showed functional alterations of several components of the host mucosal immune response to microbial pathogens. The current study shows highly relevant alterations of mRNA expression that reflect alterations in functions that predispose to the pathophysiology of IBS-D. Observations from mucosal RNA-Seq analysis. In the section of the current study that was guided by an a priori hypothesis, patients with IBS-D had reduced expression of TNFSF15, which is involved in innate immune responses (15; 33). Our prior study had shown an association of TNFSF15 genotype, particularly with IBS-C (45). Thus, genotype TNFSF15 (G allele) was associated with IBS [P ϭ 2.2 ϫ 10
Ϫ5
; odds ratio (OR) 1.37; 95% CI 1.19 to 1.58] and was predominantly due to a significant association with IBS-C (P ϭ 8.7 ϫ 10 Ϫ7 ; OR 1.79; 95% CI 1.41 to 2.26). We did observe that there was a correlation of rs4263839 genotype (GG genotype) with gene expression of TNFSF15 (mRNA levels), both in peripheral blood leucocytes and in rectal mucosal biopsies from healthy individuals (45) . IBS-C (and G allele carriers) would have greater tissue expression of TNFSF15, and we hypothesize that IBS-D would be associated with reduced tissue expression of TNFSF15, consistent with our demonstration of reduced expression of TNFSF15 mRNA in patients with IBS-D with rapid colonic transit; further studies need to be conducted in the future to validate current findings.
In the unbiased analysis section of our study, we made several novel observations that led to testable hypotheses that are relevant to the pathobiology of IBS-D and that require confirmation in the future in validation cohorts. It is important to note that the increased or decreased expressions in tissues are typically Ͼ1.5 ( Fig. 1) . Peart et al. (30) and Raouf et al. (31) declared genes to be differentially expressed if they showed a fold change of at least 1.5 and also satisfied P Ͻ 0.05 after adjustment for multiple testing, as was used in the present analysis. First, there was increased expression of two neurotransmitter ligand or receptor genes, VIP and P2RY4, that are involved in secretomotor and peristaltic reflexes, intrinsic sensory afferents and mucosal blood flow. Second, there was increased expression of two genes associated with ion channels or ion secretion, GUCA2B and PDZD3, and both control the enterocyte secretion of chloride ions through the effects of guanylate cyclase C receptor in response to endogenous ligands such as intestinal uroguanylin, which is secreted with mucins from goblet cells in normal physiological processes (13; 23). These two mechanisms may lead to increased fluid secretion and conceivably contribute to looser stool consistency in patients with IBS-D. The ileal epithelium has been shown to be more sensitive to the secretory effects of bile acids in patients with IBS-D (28). The relevance of genetic control of guanylate cyclase C receptor on the impact of clinical symptoms was clearly demonstrated in a report of an entire family diagnosed as having chronic functional diarrhea; in that family, there was a dominantly inherited, fully penetrant disease in 32 members that resulted from a missense mutation in GUCY2C (20) .
A third group of overexpressed molecules, TFF1 and RBP2, is related to tissue repair or barrier function; such expression would be important to restore normal epithelial structure, for example, in the one-third of patients with IBS-D who have evidence of malabsorption of endogenous bile acids (34; 42) that have detergent effects resulting in increased mucosal permeability. On the other hand, in the same group of barrierrelated genes, WDR72 and fibronectin 1 (FN1) are underexpressed in IBS-D relative to controls and may be responsible for the increased mucosal permeability and, possibly, the associated visceral hypersensitivity of IBS (10) .
Fourth, the overexpression of a lipid transport-related gene, lipocalin 15 (LCN15), may also be a compensatory change to the slight increase in fecal fat observed in patients with IBS-D compared with controls and patients with IBS and constipation (34; 42) . A fifth observation is that the spectrum of genes associated with interferons, responses to viruses (including myxoviruses), responses to stress (such as heat shock proteins), and innate immune responses (e.g., TNFSF15) was underexpressed in patients with IBS-D compared with controls. The Table 2 . underexpression of antimicrobial mechanisms, such as caspase 1 and lysozyme in mucosal biopsies previously demonstrated by Aerssens et al. (2) , is consistent with reduced resistance to microbes. These characteristics may conceivably predispose to postinfectious IBS (35) or the pauci-inflammatory variant of IBS, which is most commonly observed in IBS-D relative to other groups (14) . The current study did not replicate the prior observations in the study by Aerssens et al. (2) , in which five genes were expressed at higher level in mucosa from patients with IBS, with fold changes in expression Ͻ1.53 for all genes. Of these five genes with increased expression in IBS, two genes are of unclear function, one was apparently unrelated to gut function (creatine kinase, brain), two reflect mucin production (MUC20), and one gene (VSIG2) is involved in myeloid cell functions. Hence, the current data have failed to confirm upregulation of mucin gene expression, and, possibly, one gene may be associated with immune activation. It is worth noting that, although all patients in the two studies were recruited and studied in our laboratory, the report by Aerssens et al. (2) included a heterogeneous group of 36 patients (15 with IBS-C and 21 with IBS-D), whereas the current study included nine patients selected by the most accelerated colonic transit in an attempt to have as homogeneous a group as possible for the RNA-Seq analysis. Therefore, the participants in the two studies had very different phenotypes, and, because there are diverse peripheral mechanisms leading to IBS (7), we hypothesize that these are associated with differential expression of genes or posttranslational modification in the mucosa in the different subgroups of IBS. Further prospective studies of the subgroup of IBS related to epidemiologically proven relation to enteric infection are indicated to ascertain whether the observed reductions in expression occur more frequently in postinfectious cases of IBS and to appraise the time course of the disordered expression. Disorders in expression of factors protective against bacterial infection, such as cytokine and tissue repair overexpression in the current study, overexpression of mucin genes [MUC20 and V-set and immunoglobulin domain containing, 2 gene (VSIG2)] in the previous study by Aerssens et al. (2) , as well as overexpression of Toll-like receptors demonstrated by Brint et al. (6) , are all consistent with a role of microbiota and immune activation in the pathophysiology of IBS. Conversely, the underexpression of genes that protect the mucosa from luminal antigens or the inhibition of caspases that result in reduction in the apoptosis of immune cells may ultimately lead to the low-grade inflammation in IBS. Such reductions in gene expression identified in the Aerssens et al. study (2) were scavenger receptor cysteine-rich type 1 protein (M160), CD163 antigen-like 1, V-set and immunoglobulin domain-containing 4 (VSIG4), caspase 1, apoptosis-related cysteine peptidase (CASP1), IL-1␤ (convertase), neutrophil cytosolic factor 4 (NCF4), and lysozyme (LYZ). In the current study, downregulation of TNFSF15, IFIT3, MX1, HSPA1A, and HSPA1B is consistent with the same concept.
Observations from RT-PCR analysis of mRNA expression. The RT-PCR analysis demonstrated numerical up-or downregulation of genes that were in the same direction as observed on the RNA-Seq analysis, and fold changes were confirmed by both methods for five genes (P2RY4, VIP, GUCA2B, C4BPA, and FN1); there was a significant correlation between the expressions by the two methods, suggesting that the RNA-Seq data are valid. In addition, the RT-PCR analysis identified significantly increased expression of FXR gene as well as interesting numerical fold changes (all P Յ 0.10) in claudin 1, ASBT, and TNFSF15 genes. These findings are consistent with alterations in the mucosal expression of barrier, bile acid absorption, feedback regulation of synthesis, or immune activation. Importantly, ASBT expression is increased, and this is consistent with the literature that shows no evidence of mutation of the gene as a cause of bile acid malabsorption in patients with IBS (26) . Conversely, the increased expression of the nuclear receptor, FXR, is consistent with the increased production of FGF-19 and feedback regulation of hepatic bile acid synthesis in patients with IBS-D. These interesting data provide hypotheses for replication in future studies. Figure 3 summarizes the overall findings in the current studies of mRNA expression. Pathway and ingenuity analyses provided confirmatory information on the relevance of these gastrointestinal mechanisms in IBS and identified common cellular and metabolic processes that may not be specifically related to the pathobiology of IBS.
There are key limitations of this study. First, it is a pilot case-control study that requires replication. However, given the expense involved in such RNA-Seq studies, we perceive that this study provides the basis for planning future studies with regard to alterations in mucosal function, and it may allow greater focus on such mucosal mechanisms of secretion and barrier and immune functions in patients with IBS-D. Replication in a different cohort of patients with IBS-D and rapid colonic transit will inform researchers on the generalizability of the current findings. Regrettably, there are no other RNASeq studies in the current literature with which we can compare or contrast the results of the current study. However, the replication of several of the RNA-Seq fold changes by the RT-PCR data provides reassurance that the RNA-Seq data offer a rationale for future hypothesis-based studies that will be necessary to replicate these data. A second limitation is that we are unable to determine whether alterations of the transcriptome observed in the rectosigmoid mucosa of the patients with IBS-D are the cause or consequence of their condition. A third limitation is that the observations here pertain to a subgroup of patients with IBS-D and extremely fast colonic transit.
In conclusion, this pilot study demonstrates the potential utility of in-depth analysis, based on deep RNA-Seq of stored rectosigmoid mucosal biopsies, to develop greater understanding of the pathobiology of IBS-D and to help develop hypotheses for future studies. RNA-Seq and RT-PCR appear to be complementary in identifying changes in rectosigmoid mucosal mRNA expression of genes of interest. Rectosigmoid mucosa analysis by RNA-Seq and RT-PCR in IBS-D shows transcriptome changes affecting neurotransmitters, ion channels, cytokines, immune function, cell adhesion, or barrier function that provide the rationale for future validation studies to explore the role of mucosal factors in the pathobiology of IBS-D. Overall, these data continue to support the large body of evidence demonstrating the disturbances of peripheral functions in patients with IBS (7).
